Search - tctmd.com

Displaying 1 - 20 of 102

Sort: Relevancy | Date

Presentation TCT 2024

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

Presenter: Mahesh Madhavan

October 30, 2024

Presentation TCT 2024

The Impact of Access Disparities on Appropriate AS Therapy and Clinical Outcomes

Presenter: David Wood

October 30, 2024

Presentation TCT 2024

Can AI-Assisted Earlier AS Diagnosis Level the Disparities Playing Field?

Presenter: Pierre Elias

October 30, 2024

Presentation TCT 2024

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

Patient Perspectives and Shared Decision-Making in Younger Patients Requiring AS Therapy

Presenter: Megan Coylewright

October 30, 2024

Presentation TCT 2024

Surgical Valve Selection in Younger Patients with AS: Mechanical, Bioprosthetic, or Ross?

Presenter: Katherine Harrington

October 30, 2024

Presentation TCT 2024

The Emerging Use of TAVR in Younger Patients: Updates and Evidence Gaps

Presenter: Harold Dauerman

October 30, 2024

Presentation TCT 2024

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Presenter: Didier Tchetche

October 29, 2024

Presentation NY Valves 2024

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

Presenter: Philippe Pibarot

June 07, 2024

Presentation NY Valves 2024

There Is Growing Evidence to Support Earlier AS Treatment: Guidelines and Clinical Practice Are Lagging Behind!

Presenter: Philippe Genereux

June 07, 2024

Presentation NY Valves 2024

Access Disparities Affecting Appropriate AS Therapy

Presenter: David A. Wood

June 07, 2024

Presentation NY Valves 2024

Impact of Delays in Diagnosis and Treatment: Introducing the TARGET AS Program

Presenter: Brian R. Lindman

June 07, 2024

Presentation NY Valves 2024

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

Presenter: Michael J. Reardon

June 07, 2024

Presentation NY Valves 2024

Patient Interview: Understanding the Impact of Patient Preferences and Other Determinants of VHD Therapy Choices

Presenter: Robert L. Smith, Megan Coylewright

June 07, 2024

Presentation NY Valves 2024

Partner Valves: Role of a Prospective Device Selection Strategy Using Acurate and SAPIEN 3 as Complementary Devices in Transcatheter Aortic Valve Replacement

Presenter: Jonathan Michel

June 07, 2024

Presentation NY Valves 2024

Late Clinical Outcomes With Balloon Expandable Valves in Small Annulus Patients From the PARTNER Trials

Presenter: Rebecca T. Hahn

June 05, 2024

Presentation TCT 2023

I Have a Crystal Ball: What Will the AVR Universe Look Like in 2030?

Presenter: Bernard Prendergast

October 25, 2023

Presentation TCT 2023

Technical Considerations for Index TAVR in a Younger Patient

Presenter: Mariama Akodad

October 25, 2023

Presentation TCT 2023

Position 3: Initial TAVR

Presenter: Mathew Williams

October 25, 2023

Advertisement

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

The Impact of Access Disparities on Appropriate AS Therapy and Clinical Outcomes

Can AI-Assisted Earlier AS Diagnosis Level the Disparities Playing Field?

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

Patient Perspectives and Shared Decision-Making in Younger Patients Requiring AS Therapy

Surgical Valve Selection in Younger Patients with AS: Mechanical, Bioprosthetic, or Ross?

The Emerging Use of TAVR in Younger Patients: Updates and Evidence Gaps

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

There Is Growing Evidence to Support Earlier AS Treatment: Guidelines and Clinical Practice Are Lagging Behind!

Access Disparities Affecting Appropriate AS Therapy

Impact of Delays in Diagnosis and Treatment: Introducing the TARGET AS Program

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

Patient Interview: Understanding the Impact of Patient Preferences and Other Determinants of VHD Therapy Choices

Partner Valves: Role of a Prospective Device Selection Strategy Using Acurate and SAPIEN 3 as Complementary Devices in Transcatheter Aortic Valve Replacement

Late Clinical Outcomes With Balloon Expandable Valves in Small Annulus Patients From the PARTNER Trials

I Have a Crystal Ball: What Will the AVR Universe Look Like in 2030?

Technical Considerations for Index TAVR in a Younger Patient

Position 3: Initial TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content